ReviewJournal of Cancer2026
Anticancer Effects of Cepharanthine: an Updated Minireview.
Review in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cepharanthine (CEP), a bisbenzylisoquinoline alkaloid, has a long history of clinical use in Japan for various diseases. Over the past few decades, it is potent anticancer activities have garnered significant attention. In this review shows CEP exhibits anti-cancer activity via diverse mechanisms: it induces programmed cell death via intrinsic mitochondrial pathways, extrinsic death receptor signaling, and endoplasmic reticulum stress. It also arrests uncontrolled cell proliferation by causing G0/G1 and G2/M phase cell cycle arrest. Furthermore, CEP inhibits tumor progression by suppressing metastasis, invasion, and angiogenesis. It effectively modulates crucial oncogenic signaling pathways such as PI3K/Akt/mTOR, NF-κB, and JAK2/STAT3, MAPK, and plays a role in regulating oxidative stress within cancer cell. Notably, CEP can reverse multidrug resistance by inhibiting drug efflux transporters, thereby enhancing the efficacy of conventional chemotherapies, this review shows the diverse molecular targets of CEP and elucidates the complex network of pathways it modulates, positioning it as a promising natural compound for further investigation in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.